Alprostadil and dyclonine for treatment of premature ejaculation

A method of treating premature ejaculation in a patient complaining of premature ejaculation comprising:

• administering meatally to a patient in need of treatment of premature ejaculation an ejaculation latency prolonging amount of a semi-solid composition comprising:
• 0.5 percent-4.0 percent by weight based on the weight of the composition of dyclonine as a topical anesthetic;
• about 0.1 mg to about 0.5 mg of a vasoactive prostaglandin selected from the group consisting of prostaglandin E1, a pharmaceutically acceptable salt thereof a lower alkyl ester thereof wherein the lower alkyl is a straight chain or branched chain alkyl containing one to four carbon atoms, and a mixture thereof;
• a polymeric thickener selected from the group consisting of a shear-thinning polysaccharide gum and a shear-thinning polyacrylic acid polymer;
• a lipophilic component that is selected from the group consisting of an aliphatic C1 to C8 alcohol, an aliphatic C8 to C30 ester, a liquid polyol and a mixture thereof;
• about 0.25 to about 5 percent by weight based on the weight of the composition a penetration enhancer that is dodecyl 2-(N,N-dimethylamino)-propionate or a pharmaceutically acceptable salt;
• water;
• and
• a buffer system that provides a buffered pH value for said composition in the range of about 3 to about 7.4;
• wherein administering the semi-solid composition confers prolongation of baseline ejaculation latency time to the patient, thereby treating premature ejaculation in the patient.